Article
Novel Synthetic Promoter Armed Oncolytic Herpes Simplex Virus For Treatment of PAX3-FOXO1 Positive Rhabdomyosarcoma
2026-06-12
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Background</h4> Due to the difficulty in targeting oncogenic transcription factors, there are no targeted treatments available for pediatric patients afflicted with PAX3-FOXO1 fusion positive alveolar rhabdomyosarcoma. Additionally, alveolar rhabdomyosarcomas are immunologically cold tumors inherently resistant to immune checkpoint blockade. Viral vectors present a unique opportunity to add...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7e065efb-2864-5e09-baa6-b12f722a2195
- DOI
- 10.64898/2026.06.09.731216
